Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
Pecquet C, Papadopoulos N, Balligand T, Chachoua I, Tisserand A, Vertenoeil G, Nédélec A, Vertommen D, Roy A, Marty C, Nivarthi H, Defour JP, El-Khoury M, Hug E, Majoros A, Xu E, Zagrijtschuk O, Fertig TE, Marta DS, Gisslinger H, Gisslinger B, Schalling M, Casetti I, Rumi E, Pietra D, Cavalloni C, Arcaini L, Cazzola M, Komatsu N, Kihara Y, Sunami Y, Edahiro Y, Araki M, Lesyk R, Buxhofer-Ausch V, Heibl S, Pasquier F, Havelange V, Plo I, Vainchenker W, Kralovics R, Constantinescu SN. Pecquet C, et al. Among authors: havelange v. Blood. 2023 Feb 23;141(8):917-929. doi: 10.1182/blood.2022016846. Blood. 2023. PMID: 36356299 Free PMC article.
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A. Sallman DA, et al. Among authors: havelange v. Lancet Haematol. 2023 Mar;10(3):e191-e202. doi: 10.1016/S2352-3026(22)00378-7. Epub 2023 Feb 7. Lancet Haematol. 2023. PMID: 36764323 Clinical Trial.
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Blum W, et al. Among authors: havelange v. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. doi: 10.1073/pnas.1002650107. Epub 2010 Apr 5. Proc Natl Acad Sci U S A. 2010. PMID: 20368434 Free PMC article. Clinical Trial.
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.
Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon R. Havelange V, et al. Blood. 2014 Apr 10;123(15):2412-5. doi: 10.1182/blood-2013-10-532374. Epub 2014 Mar 4. Blood. 2014. PMID: 24596420 Free PMC article.
Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms.
Mambet C, Babosova O, Defour JP, Leroy E, Necula L, Stanca O, Tatic A, Berbec N, Coriu D, Belickova M, Kralova B, Lanikova L, Vesela J, Pecquet C, Saussoy P, Havelange V, Diaconu CC, Divoky V, Constantinescu SN. Mambet C, et al. Among authors: havelange v. Blood. 2018 Dec 20;132(25):2695-2699. doi: 10.1182/blood-2018-04-843060. Epub 2018 Oct 30. Blood. 2018. PMID: 30377194 Free article. No abstract available.
Targets in MPNs and potential therapeutics.
Levy G, Mambet C, Pecquet C, Bailly S, Havelange V, Diaconu CC, Constantinescu SN. Levy G, et al. Among authors: havelange v. Int Rev Cell Mol Biol. 2022;366:41-81. doi: 10.1016/bs.ircmb.2021.06.004. Epub 2021 Sep 23. Int Rev Cell Mol Biol. 2022. PMID: 35153006
The 2 faces of ERK2 in MPNs.
Havelange V, Constantinescu SN. Havelange V, et al. Blood. 2022 Jul 28;140(4):298-300. doi: 10.1182/blood.2022016536. Blood. 2022. PMID: 35900786 Free article. No abstract available.
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis.
Lecomte S, Devreux J, de Streel G, van Baren N, Havelange V, Schröder D, Vaherto N, Vanhaver C, Vanderaa C, Dupuis N, Pecquet C, Coulie PG, Constantinescu SN, Lucas S. Lecomte S, et al. Among authors: havelange v. Blood. 2023 Feb 2;141(5):490-502. doi: 10.1182/blood.2022017097. Blood. 2023. PMID: 36322928 Free PMC article.
Recent advances in therapies for primary myelofibrosis.
Vainchenker W, Yahmi N, Havelange V, Marty C, Plo I, Constantinescu SN. Vainchenker W, et al. Among authors: havelange v. Fac Rev. 2023 Sep 26;12:23. doi: 10.12703/r/12-23. eCollection 2023. Fac Rev. 2023. PMID: 37771602 Free PMC article. Review.
49 results